½ÃÀ庸°í¼­
»óǰÄÚµå
1589156

°ü»óµ¿¸Æ ¿ìȸ¼ú ±×·¡ÇÁÆ®(CABG) ½ÃÀå : ¹æ¹ý, ½Ã¼ú, Á¦Ç°º° - ¼¼°è ¿¹Ãø(2025-2030³â)

Coronary Artery Bypass Grafts Market by Method (Minimally Invasive Direct CABG, Off-Pump, On-Pump), Procedure (Double CABG Surgery, Quadruple CABG Surgery, Single CABG Surgery), Product - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 195 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

°ü»óµ¿¸Æ ¿ìȸ¼ú ±×·¡ÇÁÆ®(CABG) ½ÃÀåÀº 2023³â¿¡ 171¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú½À´Ï´Ù. 2024³â¿¡´Â 181¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, CAGR 6.19%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 260¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

°ü»óµ¿¸Æ ¿ìȸ¼ú ±×·¡ÇÁÆ®(CABG) ½ÃÀåÀº ¸·È÷°Å³ª º´µç µ¿¸Æ¿¡ Ç÷¾×À» µ¹·Á ½ÉÀåÀ¸·ÎÀÇ Ç÷·ù¸¦ °³¼±ÇÏ´Â ¿Ü°úÀû ½Ã¼ú·Î, CABGÀÇ Çʿ伺Àº Àü ¼¼°è »ç¸Á·üÀÇ ÁÖ¿ä ¿øÀÎÀÎ °ü»óµ¿¸ÆÁúȯ(CAD)ÀÇ Ä¡·á¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ¹ß»ýÇÕ´Ï´Ù. CABGÀÇ ¿ëµµ´Â ÁÖ·Î º´¿ø°ú ½ÉÀå ¼¾ÅÍ¿¡¼­ ȯÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϱâ À§ÇØ º¹ÀâÇÑ ÀýÂ÷°¡ ¼öÇàµË´Ï´Ù. CABG ½ÃÀåÀÇ ÁÖ¿ä ¼ºÀå ¿äÀÎÀ¸·Î´Â °í·ÉÈ­ ¹× »ýȰ½À°ü °ü·Ã À§Çè ¿äÀÎÀ¸·Î ÀÎÇÑ CAD À¯º´·ü Áõ°¡, ¼ö¼ú ±â¹ýÀÇ ¹ßÀü, ÇÕ¼º ¹× Á¶Á÷°øÇÐ ¿É¼Ç°ú °°Àº ÀÌ½ÄÆí Àç·áÀÇ Çõ½Å µîÀÌ ÀÖ½À´Ï´Ù. ȸº¹ ½Ã°£À» ´ÜÃàÇϰí ȯÀÚ °æÇèÀ» °³¼±ÇÒ ¼ö ÀÖ´Â ÃÖ¼Òħ½À ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ÀáÀçÀûÀÎ ±âȸ·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. »õ·Î¿î ÀÌ½Ä Àç·á ¹× ±â¼ú °³¹ßÀ» À§ÇÑ R&D ÅõÀÚ, ½ÅÈï±¹ ½ÃÀå ÁøÃâ, ´õ ³ªÀº ¾Æ¿ô¸®Ä¡¸¦ À§ÇÑ ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿ÍÀÇ ÆÄÆ®³Ê½Ê Çü¼º µîÀÌ Àü·«ÀûÀÎ Á¦¾ÈÀ¸·Î Á¦½ÃµÆ½À´Ï´Ù. ±×·¯³ª ÀÌ ½ÃÀåÀº ³ôÀº ½Ã¼ú ºñ¿ë, ±ÔÁ¦ ¹®Á¦, Ç÷°ü ¼ºÇü¼ú ¹× ½ºÅÙÆ® »ðÀÔ¼ú°ú °°Àº ´ëü Ä¡·áÀÇ °¡¿ë¼º µî ¼ºÀå ±Ëµµ¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ÇѰ迡 Á÷¸éÇØ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹®Á¦¸¦ ÇØ°áÇϱâ À§Çؼ­´Â ºñ¿ë Àý°¨ Àü·«¿¡ ÃÊÁ¡À» ¸ÂÃß°í CABGÀÇ ÀÌÁ¡À» °­Á¶Çϱâ À§ÇØ È¯ÀÚ ±³À°À» °³¼±ÇØ¾ß ÇÕ´Ï´Ù. ±â¼ú Çõ½ÅÀÌ ÇÊ¿äÇÑ ºÐ¾ß·Î´Â ³»±¸¼º°ú »ýü ÀûÇÕ¼ºÀÌ ³ôÀº ÀÌ½Ä Àç·áÀÇ °³¹ß, ·Îº¿ º¸Á¶ ¼ö¼úÀÇ ¹ßÀü µîÀÌ ÀÖ½À´Ï´Ù. ¶ÇÇÑ ºòµ¥ÀÌÅÍ¿Í AI¸¦ Ȱ¿ëÇÏ¿© Ä¡·á¸¦ Á¶Á¤Çϰí ÇÕº´ÁõÀ» ¿¹ÃøÇÔÀ¸·Î½á ȯÀÚ °á°ú¸¦ °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ±âÁ¸ ±â¾÷¿Í ±â¼ú Çõ½Å¿¡ ÁýÁßÇÏ´Â ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷µéÀÌ ¸ðµÎ Á¸ÀçÇÏ¸ç °æÀïÀÌ Ä¡¿­ÇÕ´Ï´Ù. ¼º°øÇϱâ À§Çؼ­´Â ±â¼ú ¹ßÀü, ºñ¿ë È¿À²¼º, Àü·«Àû Á¦ÈÞ¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÁøÈ­ÇÏ´Â »óȲÀ» ±Øº¹ÇØ¾ß ÇÕ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁØ ¿¬µµ(2023³â) 171¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2024³â) 181¾ï 6,000¸¸ ´Þ·¯
¿¹Ãø ¿¬µµ(2030³â) 260¾ï 5,000¸¸ ´Þ·¯
CAGR(%) 6.19%

½ÃÀå ¿ªÇÐ: ºü¸£°Ô ÁøÈ­ÇÏ´Â °ü»óµ¿¸Æ ¿ìȸ¼ú ÀÌ½Ä ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®¸¦ °ø°³ÇÕ´Ï´Ù.

°ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿ÀûÀÎ »óÈ£ÀÛ¿ëÀ» ÅëÇØ º¯È­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº Á¤º¸¿¡ ÀÔ°¢ÇÑ ÅõÀÚ °áÁ¤, Àü·«Àû ÀÇ»ç°áÁ¤, »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Æ÷ÂøÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Æ®·»µå¸¦ Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ ¿ÏÈ­Çϰí, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¹× ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • °ü»óµ¿¸ÆÁúȯÀÇ À¯º´·ü Áõ°¡
    • ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ½ÉÀå Àü¹® ÀÇ·á ¼¾ÅÍ Áõ°¡
    • CABG ¼ö¼ú¿¡ ´ëÇÑ À¯¸®ÇÑ »óȯ Á¤Ã¥
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • CABG ¼ö¼úÀÇ ÇÕº´Áõ ¹× À§Ç輺¿¡ ´ëÇÑ ¿ì·Á
  • ½ÃÀå ±âȸ
    • ·Îº¿ º¸Á¶ ¼ö¼ú µî Àúħ½ÀÀû CABG ±â¼ú °³¹ß
    • ¼ö¼ú ±â¼ú°ú ¿µ»ó±â¼úÀÇ Áøº¸
  • ½ÃÀå °úÁ¦
    • °ü»óµ¿¸ÆÁúȯ ¿¹¹æÀ» À§ÇÑ ´ëü ±â¼ú Ȱ¿ë °¡´É¼º

Portre's Five Forces: °ü»óµ¿¸Æ ¿ìȸ¼ú ÀÌ½Ä ½ÃÀåÀ» Ž»öÇÏ´Â Àü·«Àû µµ±¸

Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Portre's Five Forces ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÇ °æÀï·ÂÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ Ž»öÇÒ ¼ö ÀÖ´Â ¸íÈ®ÇÑ ¹æ¹ýÀ» Á¦°øÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» ÆÇ´ÜÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÅëÂû·ÂÀ» ÅëÇØ ±â¾÷Àº °­Á¡À» Ȱ¿ëÇϰí, ¾àÁ¡À» ÇØ°áÇϰí, ÀáÀçÀûÀÎ µµÀüÀ» ÇÇÇϰí, º¸´Ù °­·ÂÇÑ ½ÃÀå Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : °ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀå¿¡¼­ ¿ÜºÎÀÇ ¿µÇâ ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº °ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀο¡ ´ëÇÑ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ Á¦°øÇϸç, PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£µµ, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¼±Á¦ÀûÀÌ°í ´Éµ¿ÀûÀÎ ÀÇ»ç°áÁ¤À» ³»¸± Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® °ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀå¿¡¼­°æÀï ±¸µµ ÆÄ¾Ç

°ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü°ú °°Àº ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀïÀû À§Ä¡¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®Àº ½ÃÀåÀÇ ÁýÁßÈ­, ´ÜÆíÈ­ ¹× ÅëÇÕ Ãß¼¼¸¦ ÆÄ¾ÇÇÒ ¼ö ÀÖÀ¸¸ç, °ø±Þ¾÷ü´Â Ä¡¿­ÇÑ °æÀï ¼Ó¿¡¼­ ÀÚ½ÅÀÇ ÀÔÁö¸¦ °­È­ÇÒ ¼ö ÀÖ´Â Àü·«Àû ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ ÅëÂû·ÂÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º °ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀå¿¡¼­ °ø±Þ¾÷ü ¼º°ú Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â °ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº º¥´õÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±â¹ÝÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ºÎÇÕÇÏ´Â Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖÀ¸¸ç, 4°³ÀÇ »çºÐ¸éÀ¸·Î º¥´õ¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê¿Í ¼Ö·ç¼ÇÀ» ½Äº°ÇÒ ¼ö ÀÖ½À´Ï´Ù.

°ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀå¿¡¼­ ¼º°øÇϱâ À§ÇÑ Àü·« ºÐ¼® ¹× Ãßõ °ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀå¿¡¼­ÀÇ ¼º°ø °æ·Î¸¦ ±×¸®´Ù.

°ü»óµ¿¸Æ ¿ìȸ¼ú ½ÃÀå Àü·« ºÐ¼®Àº ¼¼°è ½ÃÀå¿¡¼­ ÀÔÁö¸¦ °­È­ÇϰíÀÚ ÇÏ´Â ±â¾÷¿¡°Ô ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ¿ª·® ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ½Äº°ÇÏ°í °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Á¢±Ù ¹æ½ÄÀ» ÅëÇØ °æÀï ȯ°æÀÇ µµÀüÀ» ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö ÀÖµµ·Ï ÁغñÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ Æ÷°ýÇÏ´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõµµ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ: ½ÅÈï ½ÃÀå¿¡¼­ÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÐ¾ßÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» Á¦°øÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù°¢È­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä ¹ßÀü, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ÀÇ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú ¹ßÀü µîÀ» °ËÅäÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÷´Ü ±â¼ú, ¿¬±¸ °³¹ß Ȱµ¿ ¹× Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚµéÀÌ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸®´Â µ¥ µµ¿òÀÌ µÇ´Â Áß¿äÇÑ Áú¹®¿¡ ´ëÇÑ ´äº¯µµ Á¦°øÇÕ´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå Àü¸ÁÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, ºÎ¹®, Áö¿ªÀº?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5.º¥´õ ½ÃÀå ÁøÀÔ ¹× ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • °úÁ¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • PorterÀÇ Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå °ü»óµ¿¸Æ ¿ìȸ¼ú ±×·¡ÇÁÆ®(CABG) ½ÃÀå : ¹æ¹ýº°

  • Minimally Invasive Direct CABG
  • Off-Pump
  • On-Pump

Á¦7Àå °ü»óµ¿¸Æ ¿ìȸ¼ú ±×·¡ÇÁÆ®(CABG) ½ÃÀå : ½Ã¼úº°

  • Double CABG Surgery
  • Quadruple CABG Surgery
  • Single CABG Surgery
  • Triple CABG Surgery

Á¦8Àå °ü»óµ¿¸Æ ¿ìȸ¼ú ±×·¡ÇÁÆ®(CABG) ½ÃÀå : Á¦Ç°º°

  • À§½Äµµ µ¿¸Æ
  • ³»È䵿¸Æ À̽Ä
  • ¿ä°ñ µ¿¸Æ
  • º¹Àç Á¤¸Æ À̽Ä

Á¦9Àå ¾Æ¸Þ¸®Ä«ÀÇ °ü»óµ¿¸Æ ¿ìȸ¼ú ±×·¡ÇÁÆ®(CABG) ½ÃÀå

  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦10Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ °ü»óµ¿¸Æ ¿ìȸ¼ú ±×·¡ÇÁÆ®(CABG) ½ÃÀå

  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦11Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ °ü»óµ¿¸Æ ¿ìȸ¼ú ±×·¡ÇÁÆ®(CABG) ½ÃÀå

  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦12Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®, 2023
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º, 2023
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È

±â¾÷ ¸®½ºÆ®

  • AtriCure, Inc.
  • Boston Scientific Corporation
  • Edwards Lifesciences
  • enVVeno Medical Corporation
  • Genesee Biomedical Inc.
  • Getinge AB
  • KARL STORZ SE & Co. KG
  • Medtronic PLC
  • Peters Surgical
  • Scanlan International, Inc.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Corporation
  • Transonic Systems Inc.
  • Vascular Graft Solutions Ltd.
LSH

The Coronary Artery Bypass Grafts Market was valued at USD 17.11 billion in 2023, expected to reach USD 18.16 billion in 2024, and is projected to grow at a CAGR of 6.19%, to USD 26.05 billion by 2030.

The coronary artery bypass grafts (CABG) market involves surgical procedures used to improve blood flow to the heart by redirecting blood around clogged or diseased arteries. The necessity of CABG arises from its critical role in treating coronary artery disease (CAD), a leading cause of mortality globally. Its application is primarily in hospitals and cardiac centers, where complex procedures are performed to improve patient outcomes. End-use scope is broad, addressing acute coronary symptoms in both emergency situations and elective surgeries. Key growth factors in the CABG market include the increasing prevalence of CAD due to aging populations and lifestyle-related risk factors, advancements in surgical techniques, and innovations in graft materials like synthetic and tissue-engineered options. The growing demand for minimally invasive procedures represents a potential opportunity, as it can reduce recovery times and improve patient experiences. Strategic recommendations include investing in R&D for developing novel graft materials and techniques, expanding into emerging markets, and forming partnerships with healthcare providers for better outreach. However, the market faces limitations such as the high cost of procedures, regulatory challenges, and the availability of alternative treatments like angioplasty and stenting that might affect the growth trajectory. Addressing these challenges requires a focus on cost-reduction strategies and improved patient education to highlight the benefits of CABG. Areas ripe for innovation include the development of more durable and biocompatible graft materials, as well as advancements in robotic-assisted surgeries. Additionally, big data and AI can be leveraged to enhance patient outcomes by tailoring treatments and predicting complications. The market remains competitive, characterized by both established players and new entrants focusing on technological breakthroughs. To succeed, businesses must maintain a keen focus on technological advancements, cost-efficiency, and strategic collaborations to navigate the evolving landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 17.11 billion
Estimated Year [2024] USD 18.16 billion
Forecast Year [2030] USD 26.05 billion
CAGR (%) 6.19%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Coronary Artery Bypass Grafts Market

The Coronary Artery Bypass Grafts Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of coronary artery diseases
    • Rising healthcare expenditure and growing number of cardiac specialty centers
    • Favorable reimbursement policies for CABG surgery
  • Market Restraints
    • Concerns associated with complications and risk of CABG surgery
  • Market Opportunities
    • Development of minimally invasive CABG techniques such as robotic-assisted surgery
    • Advancements in surgical techniques and imaging technologies
  • Market Challenges
    • Availability of alternate technologies for prevention of coronary artery diseases

Porter's Five Forces: A Strategic Tool for Navigating the Coronary Artery Bypass Grafts Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Coronary Artery Bypass Grafts Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Coronary Artery Bypass Grafts Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Coronary Artery Bypass Grafts Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Coronary Artery Bypass Grafts Market

A detailed market share analysis in the Coronary Artery Bypass Grafts Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Coronary Artery Bypass Grafts Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Coronary Artery Bypass Grafts Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Coronary Artery Bypass Grafts Market

A strategic analysis of the Coronary Artery Bypass Grafts Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Coronary Artery Bypass Grafts Market, highlighting leading vendors and their innovative profiles. These include AtriCure, Inc., Boston Scientific Corporation, Edwards Lifesciences, enVVeno Medical Corporation, Genesee Biomedical Inc., Getinge AB, KARL STORZ SE & Co. KG, Medtronic PLC, Peters Surgical, Scanlan International, Inc., Stryker Corporation, Teleflex Incorporated, Terumo Corporation, Transonic Systems Inc., and Vascular Graft Solutions Ltd..

Market Segmentation & Coverage

This research report categorizes the Coronary Artery Bypass Grafts Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Method, market is studied across Minimally Invasive Direct CABG, Off-Pump, and On-Pump.
  • Based on Procedure, market is studied across Double CABG Surgery, Quadruple CABG Surgery, Single CABG Surgery, and Triple CABG Surgery.
  • Based on Product, market is studied across Gastroepiploic Artery, Internal Thoracic Artery Grafts, Radial Artery, and Saphenous Vein Grafts.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of coronary artery diseases
      • 5.1.1.2. Rising healthcare expenditure and growing number of cardiac specialty centers
      • 5.1.1.3. Favorable reimbursement policies for CABG surgery
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns associated with complications and risk of CABG surgery
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of minimally invasive CABG techniques such as robotic-assisted surgery
      • 5.1.3.2. Advancements in surgical techniques and imaging technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Availability of alternate technologies for prevention of coronary artery diseases
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Coronary Artery Bypass Grafts Market, by Method

  • 6.1. Introduction
  • 6.2. Minimally Invasive Direct CABG
  • 6.3. Off-Pump
  • 6.4. On-Pump

7. Coronary Artery Bypass Grafts Market, by Procedure

  • 7.1. Introduction
  • 7.2. Double CABG Surgery
  • 7.3. Quadruple CABG Surgery
  • 7.4. Single CABG Surgery
  • 7.5. Triple CABG Surgery

8. Coronary Artery Bypass Grafts Market, by Product

  • 8.1. Introduction
  • 8.2. Gastroepiploic Artery
  • 8.3. Internal Thoracic Artery Grafts
  • 8.4. Radial Artery
  • 8.5. Saphenous Vein Grafts

9. Americas Coronary Artery Bypass Grafts Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Coronary Artery Bypass Grafts Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Coronary Artery Bypass Grafts Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AtriCure, Inc.
  • 2. Boston Scientific Corporation
  • 3. Edwards Lifesciences
  • 4. enVVeno Medical Corporation
  • 5. Genesee Biomedical Inc.
  • 6. Getinge AB
  • 7. KARL STORZ SE & Co. KG
  • 8. Medtronic PLC
  • 9. Peters Surgical
  • 10. Scanlan International, Inc.
  • 11. Stryker Corporation
  • 12. Teleflex Incorporated
  • 13. Terumo Corporation
  • 14. Transonic Systems Inc.
  • 15. Vascular Graft Solutions Ltd.
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦